Sign In
Buy DNLI
$26.48
+0.80 (+3.12%)
At Close: Jul 13, 2026
SOUTH SAN FRANCISCO, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that co-founder and Chief Executive Officer Ryan Watts, Ph.D., will deliver the o
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
03:05pm, Wednesday, 08'th Jul 2026
Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.
Denali to Sell Priority Review Voucher for $195M Cash Boost
09:40am, Friday, 19'th Jun 2026
DNLI will gain $195M from selling its Rare Pediatric Disease PRV, adding non-dilutive capital to advance its clinical portfolio and growth plans.
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
08:00am, Thursday, 18'th Jun 2026
SOUTH SAN FRANCISCO, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Pri
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
05:32pm, Friday, 05'th Jun 2026
Denali Therapeutics Inc. (DNLI) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Denali Therapeutics: 'Strong Buy' On AVLAYAH Approval And End Of 2026 FTD-GRN Data
07:54am, Wednesday, 27'th May 2026
Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiate
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
01:15pm, Friday, 22'nd May 2026
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval
02:23pm, Monday, 18'th May 2026
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval
06:08am, Saturday, 16'th May 2026
Denali Therapeutics NASDAQ: DNLI is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:00pm, Tuesday, 12'th May 2026
Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
01:41pm, Friday, 08'th May 2026
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
04:01pm, Thursday, 07'th May 2026
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval
04:33pm, Tuesday, 05'th May 2026
This biotech company develops therapies for neurodegenerative and rare diseases, supported by clinical assets and pharma collaborations.
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform
12:13am, Sunday, 03'rd May 2026
Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI's TransportVehicle technology enables
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
02:40pm, Friday, 17'th Apr 2026
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
